Canfield Scientific, Inc. v. Melanoscan, LLC

987 F.3d 1375
CourtCourt of Appeals for the Federal Circuit
DecidedFebruary 18, 2021
Docket19-1927
StatusPublished
Cited by1 cases

This text of 987 F.3d 1375 (Canfield Scientific, Inc. v. Melanoscan, LLC) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Canfield Scientific, Inc. v. Melanoscan, LLC, 987 F.3d 1375 (Fed. Cir. 2021).

Opinion

Case: 19-1927 Document: 51 Page: 1 Filed: 02/18/2021

United States Court of Appeals for the Federal Circuit ______________________

CANFIELD SCIENTIFIC, INC., Appellant

v.

MELANOSCAN, LLC, Appellee ______________________

2019-1927 ______________________

Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board in No. IPR2017- 02125. ______________________

Decided: February 18, 2021 ______________________

THOMAS LEE DUSTON, Marshall, Gerstein & Borun LLP, Chicago, IL, argued for appellant. Also represented by JULIANNE M. HARTZELL, JOHN J. LUCAS, SANDIP PATEL.

MARK D. GIARRATANA, McCarter & English, LLP, Hart- ford, CT, argued for appellee. Also represented by KEVIN REINER. ______________________

Before NEWMAN, DYK, and REYNA, Circuit Judges. NEWMAN, Circuit Judge. Case: 19-1927 Document: 51 Page: 2 Filed: 02/18/2021

Canfield Scientific, Inc. (“Canfield”) appeals the deci- sion of the U.S. Patent Trial and Appeal Board (“PTAB” or “Board”) on inter partes review (“IPR”) of U.S. Patent No. 7,359,748 (“the ’748 patent”) owned by Melanoscan, LLC. The ’748 patent “relates to the detection, diagnosis and treatment of skin cancer as well as other diseases and cos- metic conditions of the visible human.” ’748 patent, col. 1, ll. 22–24. Canfield petitioned the Board for IPR of claims 1–8, 11, 30, 32–34, 46, and 51 of the ’748 patent, asserting un- patentability on the ground of obviousness. The Board ruled that all of the challenged claims are patentable. 1 Canfield appeals, arguing that the Board erroneously re- fused to consider arguments and evidence that Canfield presented, and that the Board misapplied the law of obvi- ousness. We conclude that the Board erred in ruling that all the claims are patentable. That decision is reversed as to independent claims 1 and 51, and vacated and remanded as to the dependent claims in the petition. BACKGROUND The ’748 Patent The ’748 patent is titled “Apparatus for Total Immer- sion Photography.” The apparatus, claimed as a “device,” is an enclosure fitted with cameras and lights arranged in a manner that “allows for the imaging of total or subtotal non-occluded body surfaces in order to detect health and cosmetic conditions and involves the measurement and analysis of an optically depicted image of a patient’s sur- faces . . . .” ’748 patent, col. 1, ll. 7–11.

1 Canfield Scientific, Inc. v. Melanoscan LLC, No. IPR2017-02125, 2019 WL 1407210 (P.T.A.B. Mar. 26, 2019) (“Board Op.”). Case: 19-1927 Document: 51 Page: 3 Filed: 02/18/2021

CANFIELD SCIENTIFIC, INC. v. MELANOSCAN, LLC 3

Figure 5 is an embodiment showing the device in cross- section and octagonal shape, with lights and cameras on all sides and the subject at the center:

Figure 3 below is an alternate embodiment “utilizing a cir- cular periphery” for the device:

’748 patent, col. 18, l. 12. The ’748 patent describes the arrangement of multiple cameras and lights “vertically spaced” and “laterally spaced” on “opposite sides of the cen- terline” and adjustable to obtain the desired images of “the Case: 19-1927 Document: 51 Page: 4 Filed: 02/18/2021

person or portion thereof,” placed within the enclosure. ’748 patent, col. 21, l. 63–col. 22, l. 25. Claims 1 and 51 are the only independent claims. 1. A device for the identification of maladies that effect [sic] human tissue comprising: an enclosure configured to receive a person or por- tion thereof for imaging the person or portion thereof, wherein the enclosure defines a specified imaging position for placing the person or portion thereof within the enclosure for imaging, and the specified imaging position defines a centerline; a plurality of imaging devices, wherein a plurality of the imaging devices are vertically spaced rela- tive to each other, a plurality of the imaging devices are laterally spaced relative to each other, a plural- ity of the imaging devices are located on opposite sides of the centerline of the specified imaging po- sition relative to each other, and each imaging de- vice is located a predetermined distance relative to the specified imaging position; and a plurality of light sources spaced relative to each other and peripheral to the plurality of imaging de- vices that illuminate the person or portion thereof located at the specified imaging position and gen- erate refraction and reflectance light therefrom; wherein each of said imaging devices generates an image of the illuminated person or portion thereof located at the specified imaging position, and de- fines respective coordinates and said respective predetermined distance relative to the specified imaging position, and defines a respective focal length and resolution information, allowing precise measurement of imaged features of the person or portion thereof located at the specified imaging po- sition. Case: 19-1927 Document: 51 Page: 5 Filed: 02/18/2021

CANFIELD SCIENTIFIC, INC. v. MELANOSCAN, LLC 5

Id. Claim 51 is written in “means plus function” form for each limitation, but does not include limitations beyond those in claim 1. The Board held claims 1 and 51 to be patentable, and did not decide separate patentability of the dependent claims, all of which contain limitations in addition to those in claims 1 and 51. DISCUSSION Standard of Review Decisions of the U.S. Patent and Trademark Office (“PTO”) are reviewed on the standard of the Administra- tive Procedure Act (“APA”). Dickinson v. Zurko, 527 U.S. 150, 152 (1999). This standard applies to decisions of the PTAB. Dell, Inc. v. Acceleron LLC, 818 F.3d 1293, 1298 (Fed. Cir. 2016). In accordance with the APA, questions of law receive de novo review on appeal of the agency’s deci- sion. In re Gartside, 203 F.3d 1305, 1311, 1316 (Fed. Cir. 2000). Patentability on the ground of obviousness is a ques- tion of law, see Belden, Inc. v. Berk-Tek LLC, 805 F.3d 1064, 1073 (Fed. Cir. 2015), and receives de novo determination on appeal. Any underlying factual findings are reviewed on the APA standard of support by substantial evidence. Id. The substantial evidence inquiry requires examination of the “record as a whole, taking into account evidence that both justifies and detracts from an agency’s decision.” Gartside, 203 F.3d at 1312. The factual inquiries in an obviousness determination comprise four primary factors: the scope and content of the prior art; the differences between the prior art and the claimed invention; the level of ordinary skill in the field of the invention; and objective considerations such as com- mercial success, long-felt need, and the failure of others. Graham v. John Deere Co., 383 U.S. 1, 17 (1966). In deter- mining obviousness, the adjudicator also considers aspects Case: 19-1927 Document: 51 Page: 6 Filed: 02/18/2021

such as the motivation to select and combine specified teachings of the prior art. KSR Int’l Co. v. Teleflex, Inc., 550 U.S. 398, 400–01 (2007). The Prior Art Canfield cited five references in its petition for re- view—Voigt, Hurley, Crampton, Daanen, and Dye, out- lined as follows: Voigt Holger Voigt and Richarda Classen, Topoder- matographic Image Analysis for Melanoma Screening and the Quantitative Assessment of Tumor Dimension Parameters of the Skin, 75(4) CANCER 981 (1995) (“Voigt”) Canfield applied Voigt to all the challenged claims, in various combinations with the references to Hurley, Crampton, Daanen, and Dye.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
987 F.3d 1375, Counsel Stack Legal Research, https://law.counselstack.com/opinion/canfield-scientific-inc-v-melanoscan-llc-cafc-2021.